# Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

> **NCT02182024** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 35 (actual)

## Conditions studied

- Renal Insufficiency

## Interventions

- **DRUG:** Dabigatran etexilate high dose
- **DRUG:** Dabigatran etexilate low dose

## Key facts

- **NCT ID:** NCT02182024
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182024, "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*